
    
      This is a Phase II, Randomized, Placebo-Controlled, Double-Blinded, Clinical Trial to Assess
      Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease. 100 patients
      will be enrolled. Eligible participants are at high or very high exposure risk of contracting
      COVID-19. The primary endpoint of this study is to provide immune support against COVID-19,
      measured by the percentage of subjects that develop symptoms of COVID-19. In addition,
      participants will be monitored for overall clinical status by standard clinical laboratories
      and inflammatory markers. Participants will complete Short Form Health Survey (SF-36) and
      depression module (PHQ-9) questionnaires.
    
  